124 related articles for article (PubMed ID: 28341308)
1. Biochemical characterization and stability of immune globulin intravenous 10% liquid (Panzyga
Mersich C; Ahrer K; Buchacher A; Ernegger T; Kohla G; Kannicht C; Pock K; Römisch J
Biologicals; 2017 Jan; 45():33-38. PubMed ID: 28341308
[TBL] [Abstract][Full Text] [Related]
2. Characterization of immunoglobulin G fragments in liquid intravenous immunoglobulin products.
Diemel RV; ter Hart HG; Derksen GJ; Koenderman AH; Aalberse RC
Transfusion; 2005 Oct; 45(10):1601-9. PubMed ID: 16181211
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.
Tremblay T; Paré I; Bazin R
Transfusion; 2013 Feb; 53(2):261-9. PubMed ID: 22670706
[TBL] [Abstract][Full Text] [Related]
5. High-resolution physicochemical characterization of different intravenous immunoglobulin products.
Washburn N; Meccariello R; Hu S; Hains M; Bhatnagar N; Sarvaiya H; Kapoor B; Schaeck J; Pino I; Manning A; Lansing JC; Bosques CJ
PLoS One; 2017; 12(7):e0181251. PubMed ID: 28759653
[TBL] [Abstract][Full Text] [Related]
6. Development of an intravenous immunoglobulin with improved safety and functional activity.
Roberts PL; Dolan T; Paddick M; Stagg S; More JE
Biologicals; 2015 Mar; 43(2):123-9. PubMed ID: 25498751
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.
Borte M; Melamed IR; Pulka G; Pyringer B; Knutsen AP; Ochs HD; Kobayashi RH; Kobayashi AL; Gupta S; Strach M; Smits W; Pituch-Noworolska A; Moy JN
J Clin Immunol; 2017 Aug; 37(6):603-612. PubMed ID: 28755067
[TBL] [Abstract][Full Text] [Related]
8. Octanorm [cutaquig®], a new immunoglobulin (human) subcutaneous 16.5% solution for injection (165 mg/mL) - Biochemical characterization, pathogen safety, and stability.
Gelbmann N; Zöchling A; Pichotta A; Schmidt T; Murányi A; Ernegger T; Pock K; Römisch J
Biologicals; 2019 Jul; 60():60-67. PubMed ID: 31160148
[TBL] [Abstract][Full Text] [Related]
9. L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use.
Berger M
Immunotherapy; 2011 Feb; 3(2):163-76. PubMed ID: 21322757
[TBL] [Abstract][Full Text] [Related]
10. Interactions between immunoglobulin G molecules.
Nezlin R
Immunol Lett; 2010 Aug; 132(1-2):1-5. PubMed ID: 20600325
[TBL] [Abstract][Full Text] [Related]
11. Biochemical Characterization of a New 10% IVIG Preparation [IgG Next Generation (BT595)/Yimmugo
Duellberg C; Hannappel A; Kistner S; Maneg O
Drugs R D; 2023 Sep; 23(3):245-255. PubMed ID: 37466834
[TBL] [Abstract][Full Text] [Related]
12. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
McCormack PL
BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
14. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
[TBL] [Abstract][Full Text] [Related]
15. ASHP therapeutic guidelines for intravenous immune globulin. ASHP Commission on Therapeutics.
Clin Pharm; 1992 Feb; 11(2):117-36. PubMed ID: 1312920
[No Abstract] [Full Text] [Related]
16. A newer immunoglobulin intravenous (IGIV) - Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care.
Shah SR
Expert Opin Biol Ther; 2008 Jun; 8(6):799-804. PubMed ID: 18476791
[TBL] [Abstract][Full Text] [Related]
17. The antiinflammatory IgG.
Kaveri SV; Lacroix-Desmazes S; Bayry J
N Engl J Med; 2008 Jul; 359(3):307-9. PubMed ID: 18635437
[No Abstract] [Full Text] [Related]
18. Should therapeutic immunoglobulin be considered a generic product? An evidence-based approach.
Misbah SA
J Allergy Clin Immunol Pract; 2013; 1(6):567-72. PubMed ID: 24565702
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic intravenous immunoglobulins.
Lemieux R; Bazin R; Néron S
Mol Immunol; 2005 May; 42(7):839-48. PubMed ID: 15829272
[TBL] [Abstract][Full Text] [Related]
20. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution.
Szenczi A; Kardos J; Medgyesi GA; Závodszky P
Biologicals; 2006 Mar; 34(1):5-14. PubMed ID: 16168667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
